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AAV-mediated photoreceptor transduction of the pig
cone-enriched retina
C Mussolino1,2, M della Corte3, S Rossi3, F Viola4, U Di Vicino1, E Marrocco1, S Neglia1, M Doria1, F Testa3,
R Giovannoni5, M Crasta6, M Giunti7, E Villani4, M Lavitrano5, ML Bacci7, R Ratiglia4, F Simonelli1,3,
A Auricchio1,8 and EM Surace1
Recent success in clinical trials supports the use of adeno-associated viral (AAV) vectors for gene therapy of retinal diseases
caused by defects in the retinal pigment epithelium (RPE). In contrast, evidence of the efficacy of AAV-mediated gene transfer
to retinal photoreceptors, the major site of inherited retinal diseases, is less robust. In addition, although AAV-mediated RPE
transduction appears efficient, independently of the serotype used and species treated, AAV-mediated photoreceptor gene
transfer has not been systematically investigated thus so far in large animal models, which also may allow identifying relevant
species-specific differences in AAV-mediated retinal transduction. In the present study, we used the porcine retina, which has a
high cone/rod ratio. This feature allows to properly evaluate both cone and rod photoreceptors transduction and compare the
transduction characteristics of AAV2/5 and 2/8, the two most efficient AAV vector serotypes for photoreceptor targeting. Here we
show that AAV2/5 and 2/8 transduces both RPE and photoreceptors. AAV2/8 infects and transduces photoreceptor more
efficiently than AAV2/5, similarly to what we have observed in the murine retina. The use of the photoreceptor-specific rhodopsin
promoter restricts transgene expression to porcine rods and cones, and results in photoreceptor transduction levels similar to
those obtained with the ubiquitous promoters tested. Finally, immunological, toxicological and biodistribution studies support
the safety of AAV subretinal administration to the large porcine retina. The data presented here on AAV-mediated transduction of
the cone-enriched porcine retina may affect the development of gene-based therapies for rare and common severe photoreceptor
diseases.
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INTRODUCTION
The recent promising results of gene therapy in patients with leber
congenital amaurosis (LCA1), the most severe form of inherited
childhood blindness, supports the safety and efficacy of retinal gene
transfer through adeno-associated viral (AAV) vectors.2–7 The ther-
apeutic success behind the LCA trials is mainly because of two factors:
(1) the availability of vectors that enable an efficient transduction of
the retinal pigment epithelium (RPE), the target cells in LCA2, the
specific LCA form selected for the trials; and (2) the availability of a
relevant LCA2 large animal model. The consistency of the data relative
to the safety and efficacy of gene transfer obtained in LCA2 models as
diverse as mice,8 dogs9 and humans, strongly supports the concept
that AAV-mediated RPE-specific gene transfer may be extended from
animal models to humans.
Owing to its simple monolayer organization, and its functional and
biological properties,10 the RPE is efficiently transduced by virtually
any AAV vector serotypes tested.11,12 However, the majority of
inherited forms of retinal diseases affect rod and/or cone photorecep-
tors, whose transduction poses greater difficulties compared with the
RPE. To date, only a few AAV serotypes have been shown to efficiently
target animal model photoreceptors and a systematic side-by-side
comparison of large animal photoreceptor transduction by different
AAV serotypes is still lacking.12 Notwithstanding, the data available
thus far suggest that AAV2/5 and AAV2/8 efficiently transduce
photoreceptors in rodents,11,13–16 whereas AAV2/2, AAV2/5 and
AAV2/8, independently tested, appear to be efficient in transducing
photoreceptors in dogs,9,17,18 and non-human primates (NHP).19–22
In addition, owing to limitations of the experimental models used, the
difference between rod and cone transduction remains difficult to
assess. In particular, the distribution and number of cone photore-
ceptors in the murine retina represents a major limitation to precisely
define their transduction, whereas the primate retina, which generally
is considered dominated by cones, has on average a relatively low
cone/rod ratio (1:20 in humans23). The porcine eye presents a high
cone/rod ratio distributed throughout the retina (an overall average
cone/rod ratio of 1:7) and a large cone-rich streak region encompass-
ing the horizontal meridian where the cone/rod ratio reaches 1:3/1:5.24
Thus, pigs represent an ideal large animal model to study cone
transduction characteristics also compared with the NHP retina, in
which the cone/rod ratio is low (1/15) beyond the small foveal area.23
The abundance of both rods and cones makes the porcine retina
particularly amenable to determine the transduction of the single
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photoreceptor cells following subretinal administration of viral vec-
tors. In addition, the porcine eye, more than that of other large
mammals such as dogs and cows,25 shares many similarities with the
human retina including, a nontapetal fundus with a holangiotic
vascular pattern and the presence of retinal layers of similar thickness.
The size and anatomy of the porcine eye globe, lens and cornea offer
the possibility to test the feasibility of vitreo–retinal surgery techniques
such as the subretinal injection of viral vectors. In addition, various
porcine models of genetic and acquired retinal diseases are avail-
able.26–28
We therefore sought to compare the transduction efficiency of
AAV2/5 and 2/8 in the porcine retina, as well as that of ubiquitous
and photoreceptor-specific promoter elements.
RESULTS AND DISCUSSION
Subretinal administration of AAV vectors to the porcine retina
In this study, we injected 46 eyes subretinally either monolaterally or
bilaterally from 11-week-old pure Large White female pigs (n¼29; live
weight¼33±2 kg). To target a region of the retina with a similar cone
and rod photoreceptor content, AAV vectors were subretinally inocu-
lated in the avascular nasal area of the posterior pole between the two
main vascular arches (Figure 1a) in which cone density reaches
35 000 cells per mm2 (see ref. 24). In the first set of experiments, in
which our aim was to define the best serotype for photoreceptor
transduction, we performed a traditional surgical procedure using 20-
gauge instrumentation for vitrectomy. In the subsequent experiments
comparing promoter efficiency, we switched to a 23-gauge technique
with the aim of reducing surgical trauma providing numerous
potential advantages, including faster wound healing, diminished
conjunctival scaring with less post-operative redness and inflamma-
tion (see the Materials and Methods section). The AAV vector
serotypes to be tested were either co-injected with AAV2/1-cytome-
galovirus (CMV)-LacZ for normalization or injected alone (see
below). We injected 1.0–2.01010 genome copies (GCs) of each vector
in a total volume of 100ml. To avoid lot-to-lot differences, two
independent vector preparations per serotype/promoter construct
were used. Subretinal vector administration resulted in the typical
‘dome-shaped’ retinal detachment (retinal bleb: Figure 1a). All animals
underwent ophthalmologic examination within the first 3 days follow-
ing surgery and at killing (6 weeks post-vector administration).
Adverse events included inflammation, which spontaneously resolved:
five irreversible retinal detachments (10.8% of the treated eyes, all of
which occurred at the beginning of experimentations when we were
setting the surgical procedure), and 15 limited opacities of the poster-
ior capsule in correspondence of the entry site of surgical instruments.
AAV2/8 transduces porcine photoreceptors more efficiently than
AAV2/5
To evaluate the tropism of different AAV vector serotypes, following
subretinal administration in pigs, we generated AAV2/5 and 2/8
vectors expressing the enhanced green fluorescent protein (EGFP)
from the CMV promoter (AAV2/5-CMV-EGFP; AAV2/8-CMV-
EGFP). Initially, nine Large White female pigs were subretinally
co-injected with an AAV2/1-LacZ encoding for Escherichia coli
b-Galactosidase (b-Gal), to control over the potential variability of
AAV vectors administration following subretinal surgery13 (n¼5 eyes
Figure 1 Tropism of AAV2/5 and AAV2/8 vectors subretinally injected in the porcine retina. (a, right panel) Schematic representation of the visual streak in
the porcine retina with highest cone density (light blue; re-drawing from reference 24). The light green area represents the site and the extension of
subretinal injection. (a, middle panel) Assembly of black and white fundus images showing dome-like retinal bleb following subretinal injection of 100ml of
AAV vector containing- solution. The asterisk indicates the injection site. (b) Confocal fluorescence microscopy analysis of retinal sections at 6 weeks after
subretinal injection of AAV2/5-, or AAV2/8-CMV-EGFP. (b, upper panel) Outer retinal EGFP expression appearance (20 magnification). Arrows indicate
EGFP-positive cells in the inner nuclear layer (INL). The images of the INL were taken at higher exposure than those of the outer retina. RPE, retinal
pigment epithelium; ONL, outer nuclear layer (scale bar¼10mm). (b, lower panels) Cone transduction by the different AAV serotypes. Co-localization of EGFP
expression and PNA-lectin staining (cone sheats in red) evaluated by confocal microscopy (scale bar¼100mm).
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injected per serotype; n¼3 eyes untreated; at a dose of 1.01010GC
for each vector). At 6 weeks after injection, the animals were
killed to perform histological analysis and to measure EGFP expres-
sion levels.
Confocal microscopy analyses of EGFP-positive areas dissected out
from the most transduced retinal portion showed robust transduction
of both the RPE and photoreceptor cells with both AAV2/5 and 2/8
(Figure 1b, lower panels). In addition, cells resident in the inner
nuclear layer with a shape similar to Mu¨ller cells glia (cellular bodies
encompassing the entire retinal thickness) were EGFP positive
(Figure 2b, lower panels). To assess the ability of the AAV serotypes
tested to transduce cone photoreceptors, we stained the cone outer
segments with peanut agglutinin-lectin. Confocal immunofluores-
cence analysis revealed that cones, in addition to rods, were efficiently
transduced by all AAV serotypes tested (Figure 2a, lower panels).
Fluorescence imaging of the whole-mounted retinas showed robust
and homogeneous EGFP expression in the region exposed to the
AAV2/5 vector, whereas fluorescence in the retinas treated with AAV 2/
8 appeared weaker (Figure 2a, upper panels).
To quantify AAV-mediated porcine photoreceptor transduction
levels, EGFP expression was measured in peeled retinas from treated
(n¼4) and untreated eyes (n¼2) by western blot and normalized
against a housekeeping protein (b-tubulin; Figure 2a). As RPE cells are
carefully removed from peeled retinas, EGFP expression levels mainly
reflect photoreceptor transduction following subretinal administra-
tions of AAV vectors containing the CMVubiquitous promoter. EGFP
expression levels following AAV2/5 administration was threefold
higher than AAV2/8 (Figure 1a) or 12-folds if considering values
normalized with b-Gal (ratio EGFP/b-Gal; data not shown). These
data would suggest that AAV2/5 is more efficient at transducing
porcine photoreceptors than the AAV2/8 serotype. To rule out the
possibility that co-injection of the AAV2/1 might have interfered with
AAV2/5 or AAV2/8 transduction, AAV2/5-CMV-EGFP or AAV2/8-
CMV-EGFP were subretinally injected either alone (n¼4 eye per
serotype; 1.01010 GC per eye); or with 1.6109 or 1.01010 GC
per eye of AAV2/1-LacZ (corresponding to 1:1 or 1:6, respectively, of
the dose of AAV2/5 or AAV2/8; n¼2 eye per serotype). Whole-
mounted stereo-microscopy fundus appearance showed similar
EGFP signal between AAV2/5 and AAV2/8 when injected alone
(Figure 2b), whereas AAV2/8, but not AAV2/5, showed less EGFP
signal when co-injected with AAV2/1 (Figure 2a). Western blot
analysis showed that AAV2/8 provided fivefold higher EGFP expres-
sion than AAV2/5 when injected without AAV2/1. In addition, AAV2/8
displayed an AAV2/1 dose-dependent decrease of retinal transduction
(Figure 2b). We thus conclude that AAV2/8 is a more robust gene
delivery vehicle for photoreceptors transduction than AAV2/5 (as we
have previously demonstrated in mice15). This is in agreement with a
previous study in dogs,17 which however lacked the side-by-side
comparison between the two AAV serotypes that we have performed.
Consistent with this observation, two additional studies have demon-
strated that AAV2/8-mediated gene complementation enables signifi-
cant protection from severe photoreceptor degeneration in a mouse
model of LCA29 (likely owing to the limited efficiency of photorecep-
tor gene transfer provided by previously tested AAV serotypes).
The data presented here underscore that the photoreceptor gene
transfer properties of AAV2/8 are conserved among different species.
Figure 2 AAV-mediated transduction of the porcine retina. (a) Fundus fluorescence imaging of the whole-mounted retinas showed higher EGFP expression in
AAV2/5- than AAV2/8 treated retinas when co-injected with AAV2/1 (Figure 1a, upper panels). (a, Lower panel) Western blot analysis with anti-EGFP (upper
blot) or anti-b-tubulin (lower blot) antibodies of lysates from swine retinas transduced with AAV-2/5, -2/8 (n¼4 for each serotype). (a, Lower right) Histogram
representing the EGFP expression levels measured by western blot. In the histogram values of EGFP (pixels inches1) normalized against b-tubulin
(pixels inches1) are reported (n¼4 eyes per group; *AAV2/5 vs AAV2/8: P¼0.0098). (b) Fundus appearance (upper left) and quantification of the EFGP
expression levels (upper right and lower panels) by western blot analysis of porcine retinas injected with AAV2/5-CMV-EGFP or AAV2/8-CMV-EGFP alone
(n¼4 eyes per group; *AAV2/5 vs AAV2/8: P¼0.00014).
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This result is not trivial considering other studies in which different
interspecies transduction levels were observed for the same AAV
serotype.30–33
Our data also show that AAV2/1 inhibits AAV2/8 retinal transduc-
tion. This suggests that the two vectors may compete for similar
receptors/co-receptors or post-entry pathways.
Ubiquitous and photoreceptor-specific promoters are similarly
efficient in porcine photoreceptor transduction
To select the most efficient promoter for porcine photoreceptor
transduction, we generated AAV2/5 vectors encoding EGFP under
the transcriptional control of the cytomegalovirus (CMV34), Chicken-
b-actin (CBA35) ubiquitous promoters or the human rhodopsin
(RHO36) photoreceptor-specific proximal promoter (U16824 Gene-
Bank; sequence, 800 to +6), namely AAV2/5-CMV-EGFP, AAV2/5-
CBA-EGFP and AAV2/5-RHO-EGFP, respectively. At 6 weeks after
subretinal administration, the eyes and the retinas were collected for
histological (n¼2 eyes per group; n¼1 untreated) and western blot
analyses of EGFP expression (n¼3 eyes pet group; n¼2 untreated). As
expected from previous studies in mice, the EGFP expression pattern
from AAV2/5 vectors harboring the CMVor the CBA promoters11,13,14
was localized to both RPE and photoreceptors, whereas the RHO
promoter restricted transgene expression to photoreceptors (Figure 3a,
upper panels13,36). In addition, co-localization of EGFP and peanut
agglutinin staining evaluated by confocal microscopy analysis demon-
strated an efficient EGFP expression in cone photoreceptors indepen-
dently of the promoter used (Figure 3a, lower panels). We next
quantified the EGFP expression levels in the retinas treated with
AAV2/5 vectors harboring different promoters by western blot analysis
(Figure 3b) as described in the previous paragraph. Subretinal
administration of AAV2/5 vectors containing ubiquitous (CBA or
CMV) and photoreceptor-specific (RHO) promoters resulted in
similar EGFP expression levels with a slightly higher, although not
statistically significant, EGFP/b-Gal ratio in samples treated with the
vector containing the EGFP driven by the RHO promoter (Figure 3c).
Although the EGFP levels obtained using the RHO promoter faithfully
represent both cone and rod photoreceptor transductions, those using
the CBA and CMV promoters may additionally reflect transduction of
a few contaminating RPE and inner retinal cells. The relative levels of
transduction obtained in the porcine retina using the RHO promoter,
compared with the ubiquitous CMV and CBA, differ from what we
observed previously in the murine retinas, in which the use of the
same RHO promoter element led to the highest reporter gene
expression levels. The transcriptional activity of the RHO promoter
is likely to be higher in rods than cones, thus resulting in higher
transduction levels in the murine rod-dominant than in the porcine
cone-enriched retina.
Retinal function, histopathology, neutralizing antibodies and vector
biodistribution following AAV subretinal administration in pigs
To assess whether AAV vector administration and/or the surgical
technique applied resulted in detrimental effects on retinal function,
full-field electroretinograms (ERGs) were recorded at baseline and
before killing (Figure 4). Rod and cone traces were evaluated sepa-
rately. Both rod and cone isolated responses of treated eyes (recorded
at 6 weeks after vector delivery) showed no statistical difference
compared with baseline preoperative values recorded the day of
surgery (Figures 4a-d; baseline pre-treatment n¼6, post-treatment
n¼5). On the contrary, in the animal with retinal detachment, the
ERG was not recordable (Supplementary Figure 1). Interestingly, the
Figure 3 Subretinal injections of AAV2/5 vectors expressing EGFP from ubiquitous and photoreceptor-specific promoters. (a, Upper panels) Confocal
fluorescence microscopy images (63 magnification) of retinal sections showing EGFP expression from cytomegalovirus (CMV), Chicken-b-actin (CBA) or
human rhodopsin (RHO) promoters (Scale bar¼100mm). (a, Lower panels) Cone transduction is indicated by the co-localization of EGFP expression and PNA
staining (arrows). RPE, retinal pigment epithelium; ONL, outer nuclear layer (scale bar¼100mm). (b) Western blot analysis with anti-EGFP (upper blot) or
anti-b-tubulin (lower blot) antibodies of lysates from porcine retinas transduced with AAV-2/5-EGFP driven by CMV, CBA or RHO promoters. (c) In the left
histogram, values of EGFP (pixels inches1) normalized against b-tubulin (pixels inches1) are reported (n¼3 for each serotype).
Figure 4 Safety of AAV vector delivery to porcine retinas. Electroretinographic recordings at baseline (pretreatment) and at killing (post treatment).
(a–d) Comparison of the tracings derived from representative eyes before and after subretinal injections of AAV vectors. The histograms show the maximum
B-wave average response of all recorded eyes (n¼6 eyes pre-treatment; n¼5 eyes post treatment). (a) Rod responses (dark-adapted conditions); (b) Maximal
response (A-wave and B-wave) of rods and cones (dark-adapted conditions, single white flash); (c) Cone responses isolated using a bright single flash (light-
adapted conditions, background white light); (d) Cone responses isolated using a flicker response (light-adapted conditions). (e) Immunofluorescence image
(20 magnification) of retinal sections from animals injected with AAV2/5 or 2/8 and stained with glial fibrillary acidic protein (GFAP; in red) as marker
of gliosis. EGFP expression (in green) shows the transduced area. RPE, retinal pigment epithelium; ONL, outer nuclear layer; INL, inner nuclear layer
(scale bar¼10mm).
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electrophysiological measurements showed high photopic and low
scotopic amplitudes compared with those of NHP and humans,21,37
demonstrating a predominant contribution of cone photoreceptors to
the ERG responses in porcine retinas. The ERG findings support the
concept that both cone and rod photoreceptor functions were pre-
served after AAV2/5, and 2/8 subretinal administration.
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To investigate the presence of neutralizing antibodies (NAbs) to the
AAV vector capsids, serum and anterior chamber fluid samples were
collected at the day of surgery and at killing (at 6 weeks after injection)
from all animals injected subretinally with AAV vectors.19,38 Out of 21
animals tested, including those with retinal detachment (AAV2/5
n¼11 and AAV2/8 n¼5) only 3 animals developed NAbs in the
serum (one per AAV serotype injected) after treatment, whereas a
modest increase of NAb levels was detected in the anterior chamber
fluids of one animal (P19 left eye) with retinal detachment (Supple-
mentary Figure 3).
Histopathological analyses (hematoxilin and eosin staining) of
retinal sections evaluated at killing, revealed normal retinal histology,
including lack of inflammatory cell infiltrates in the eyes treated with
the different AAV vectors tested (Figure 4e, lower panels). Histo-
pathological analysis performed on one eye with retinal detachment at
ophthalmological visit showed RPE atrophy, hypertrophy of melano-
cytes and RPE cells, and extensive degeneration of the outer nuclear
layer and photoreceptor outer segments (Supplementary Figure 1).
To assess whether AAV injections induced gliosis in the transduced
retinas, we performed glial fibrillary acidic protein (red) staining of
retinal sections at killing. As shown in Figure 4e, no significant
differences were observed among the retinal sections derived from
treated and/or untreated retinas. To evaluate whether either the
surgical procedure or the AAV-mediated transduction induce photo-
receptor apoptosis in the cells, TUNEL staining was performed on
retinal sections of treated and untreated eyes. This analysis was also
performed from retinal sections of one eye with retinal detachment
(Supplementary Figure 2). We did not observe apoptotic nuclei
(TUNEL stained; red), suggesting that the degeneration caused by
retinal detachment occurred before collecting.
To determine AAV biodistribution following subretinal delivery to
the porcine retina, we extracted HIRT DNA from the following: the
optic nerve, optic chiasm, visual thalamus, visual occipital cortex,
muscle (tongue), lung, liver, spleen, ovaries and peripheral blood
mononuclear cells. Samples were analyzed by real-time PCR (n¼11
animals) with primers specific for the AAV genome. Table 1 reports
AAV2/5 or AAV2/8 biodistribution in the retina and in different areas
of the brain, including one animal with retinal detachment (P3;
Table 1, asterisk). The results support the presence of AAV genomes
in all retinas and in two optic nerves and not in the brain (Table 1) or
the other extraocular tissues analyzed (data not shown). These results
indicate that the risk of the vector spreading outside the treated tissue
is minimal at the AAV doses used in this study. Previous studies
reported the presence of AAV vector genomes in the lateral geniculate
nucleus of NHP that received AAV2/2 subretinal injections,20 whereas
vector DNA, EGFP mRNA and EGFP protein were found in neurons
of the lateral geniculate nucleus contralateral to the injected eye and in
several parts of the brain after subretinal delivery of AAV2/8 in dogs,17
suggesting that trans-synaptic transport of vector particles had
occurred. In the present study, the presence of AAV genomes in two
optic nerves associated with the lack of genomes in the thalamus and
occipital cortex favors the hypothesis that accidental leakage of vector
solution in the vitreous during subretinal infusion may result in
infections of retinal ganglion cells. Altogether, these data support
the safety of AAV vectors subretinal administration to the porcine eye.
The side-by-side comparison of the porcine retinal transduction
characteristics, following subretinal administration of AAV2/5 and
AAV2/8 vectors serotypes herein reported shows that: (1) both vectors
efficiently transduce photoreceptors and RPE; (2) AAV2/8 transduces
at higher levels than AAV2/5 the porcine cone-enriched outer retina;
and (3) both the ubiquitous and photoreceptor-specific promoters
tested here allow similar levels of porcine retinal transduction. Given
the high cone/rod ratio of the porcine retina, and the genetic and
physiological similarities between pigs and humans, our data may
affect the development of gene-based therapies for rare and common
retinal diseases affecting both rod and cone photoreceptors.
In addition, the pig may be considered as a valuable bridging
animal model to assess tropism and safety of retinal gene transfer
before proceeding to the formal good laboratory practice toxicity
studies in NHP, typically required by regulatory agencies for a human
clinical trial.
MATERIALS AND METHODS
Generation of the plasmid constructs
For the production of AAV-encoding EGFP with different promoters, pAAV2.
1-CMV-EGFP,39 pAAV2.1-CBA-EGFP and pAAV2.1-RHO-EGFP plasmids
were used. pAAV2.1-RHO-EGFP and pAAV2.1-CBA-EGFP were obtained by
exchanging the CMV promoter of pAAV2.1-CMV-EGFP with the RHO (800
to +6 relative to the transcriptional start site; GenBank accession number
U16824) or the CBA promoters. The RHO promoter was PCR amplified from
the human genomic DNA to insert the NheI and NotI sites at the 5¢ and 3¢ ends,
respectively, using the following primers: NheI-RHO-Forward, 5¢-AATTATGCT
AGCAGATCTTCCCCACCTAGC-3¢ and NotI-RHO-Reverse, 5¢-ATTAATGC
GGCCGCGGATGACTCTGGGTTCTG-3¢. The PCR product was then digested
with NheI and NotI and cloned in AAV2.1-CMV-EGFP after removing the
CMV promoter. The CBA promoter was amplied from the pCAGGS plasmid
(a kind gift by M Studer, TIGEM, Naples, Italy) by PCR to insert the NcoI and
PstI sites at the 5¢ and 3¢ ends, respectively. The PCR product was then cloned
Table 1 Biodistribution following subretinal delivery in pigs (GCmdg1)
Treatment Retina Optic nerve Chiasm Thalamus Visual cortex
R1 Left AAV2/8 6.771±0.205 ND ND ND ND
R2 Left AAV2/8 Not measured ND ND ND ND
R3 Left AAV2/8 2.340±0.043 ND ND ND ND
R4 Left AAV2/8 2.552±0.126 ND ND ND ND
R5 Left AAV2/5 4.952±0.379 ND ND ND ND
Right AAV2/5 34.344±0.094 0.491±0.005 ND ND ND
R6 Left AAV2/5 58.104±1.480 0.444±0.002 ND ND ND
Right AAV2/5 Not measured ND ND ND ND
P3 Left AAV2/5-RHO Not measured ND ND ND ND
Right* AAV2/5-CMV Not measured ND ND ND ND
Right Not Injected ND ND ND ND ND
Abbreviations: GC, genome copies; mdg, molecule of diploid genome; nd, not detected. Asterisk indicates eye with a retinal detachment.
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into pAAV2.1-CMV-EGFP (digested with NcoI and PstI) downstream of the CMV
enhancer. The pAAV2.1-CMV-LacZ plasmid has been previously described.39
AAV vector production
AAV vectors were produced by the TIGEM AAV Vector Core (Naples, Italy)
using the pAAV2.1-CMV-EGFP, -CBA-EGFP, -RHO-EGFP and -CMV-LacZ
plasmids. Recombinant AAV2/5, and 2/8 viruses were produced by triple
transfection of 293 cells followed by cesium chloride purication.11 For each
viral preparation, physical titers (in (GC) per ml) were determined by both
PCR quantication using TaqMan (PerkinElmer Life and Analytical Sciences,
Boston, MA, USA) and dot-blot analysis.40
Animals and subretinal administration of AAV vectors
All the experiments regarding animals were conducted according to the rules
approved by the Italian Institution for animal research. The Large White pigs
used in our study were registered as purebred in the LW Herd Book of the Italian
National Pig Breeders’ Association. Pigs were starved overnight leaving water
ad libitum.
Before surgery, eyes were dilated with topical 2.5% phenylephrine (Bausch &
Lomb Ltd., London, UK). The surgical procedure envisaged two-port scler-
otomy, one for the light source and the other for the injection. Briefly, one drop
of 5% povidone iodine solution (Betadine, Meda Pharma, Milano, Italy) was
applied to the ocular surface and in the cul-de-sac for 3min, followed by
insertion of lid speculum. The procedure started with a transconjunctival
scleral tunnel incision via pars plana parallel to the corneoscleral limbus at
3.5mm. The angle insertion of 20- or 23-gauge stiletto blade (Alcon, Fort
Worth, TX, USA) was performed for every case to facilitate the efficiency of
self-sealing. Subsequently the light fiber attached to the vitrectomy unit
(ACCURS vitrectomy machine, Alcon) and either a 38-gauge (Alcon) or
extendible 41-gauge subretinal injection needles (DORC, Zuidland, the Nether-
lands) were, respectively, inserted through the two conjunctival incisions and
into the two scleral tunnels. Therefore, illuminating the posterior pole with the
light fiber and without vitreous removal, the injection in the subretinal space in
the nasal area was performed with a 1-ml syringe connected to the subretinal
needles, slowly and under direct observation with a stereoscopic microscope. At
the end of surgery, paracentesis with removal of 0.1ml of aqueous humor was
performed using a 1-ml syringe with 30-gauge needle to collect anterior
chamber fluid sample (preoperative) and to avoid an increase in intraocular
pressure. Animals underwent handy slit-lamp biomicroscopy and indirect
ophthalmoscopy before and immediately after injection, within 3 days after
surgery and at killing at 6 weeks post-vector administration.
Anesthetic procedure
Premedication included intramuscular injection of azaperone (2mg kg1 of
Stresnil, Janssen-Cilag SpA, Milano, Italy). Pigs were left undisturbed for
20mins and then received a second intramuscular injection of ketamine
(20mgkg1 of Ketavet 100, Intervet Productions S.r.l., Segrate, Italy), acepro-
mazine (100mg kg1 of Prequillan, ATI S.r.l., Bologna, Italy) and atropine
(0.04mgkg1 of Atropina solfato, ATI S.r.l.). An auricular vein was catheterized
by the insertion of an over-the needle catheter (Delta Ven1, DELTA MED S.r.l.,
Mantova, Italy) and a saline solution was infused i.v. at a rate of 10ml kg1 per
hour. General anesthesia was induced and maintained by intermittent i.v.
boluses of ketamine (5mgkg1 of Ketavet 100, Intervet Productions S.r.l.) and
diazepam (0.5mgkg1 of Diazepam 0.5%, Intervet Productions S.r.l.) during
the whole ERG procedure. Animals were then moved to the surgery room
where they were orotracheally intubated, following an i.v. bolus of sodium
thiopental (5–10mg kg1 of Pentothal Sodium, Intervet Productions S.r.l.).
During the surgical procedure, anesthesia was maintained with isoflurane in
100 % oxygen and pigs were mechanically ventilated (Falco 201, Siare Hospital,
Bologna, Italy) setting a tidal volume and a respiratory rate to maintain
end-tidal PCO2 between 35 and 45mmHg.
Fundus photography
Eyecups were collected, fixed by immersion in 4% paraformaldehyde for 12h
and then rinsed briefly with phosphate-buffered saline (Sigma, St Louis, MO,
USA). Cornea and lenses were removed and fundus photographs were taken
with an Axioplan microscope (Carl Zeiss, Oberkochen, Germany) in bright
field and under fluorescence light to evaluate the EGFP expressing area.
Sampling of the anterior chamber fluid, vitreous and retina
Pigs were anesthetized as described above and killed, following ERG procedure
and blood sampling, with an i.v. administration of 10ml of Tanax (Intervet
Italia, Segrate, Italy), and their eyeballs were collected using a pair of scissors to
cut the muscles and the optic nerve. Each eye was placed in a petridish filled
with phosphate-buffered saline and rinsed twice. The conjunctiva and tendons
were cleaned off the globe and a 33-gauge needle connected to a syringe was
used to aspirate the anterior chamber liquid. The fluid was placed in an
Eppendorf tube (Eppendorf, Hamburg, Germany) for the detection of the
NAbs and immediately frozen in liquid nitrogen. A scalpel was used to dig into
the eye and vannas scissors (WPI, Sarasota, FL, USA) were used to separate the
anterior chamber including the iris and lens from the eyecup. Special care was
given to avoid compressing the eye. To prevent any suction of the retina, the
vitreous was carefully aspirated by using a syringe without a needle, placed in
an Eppendorf tube (Eppendorf) and immediately frozen in liquid nitrogen.
The eyecup was then cut in 4–5 parts and the retina was detached from the RPE
using a scraper. The attachment to the optic nerve was then severed and
the retina was collected with blunt forceps, placed in an Eppendorf tube
(Eppendorf) and immediately frozen.
Histological analysis
Pigs were killed and their eyeballs were collected and fixed overnight by
immersion in 4% paraformaldehyde. The eyeballs were cut so that the lens
and vitreous could be removed, leaving the eyecups in place. Tissue-freezing
medium (OCT matrix, Kaltek, Padua, Italy) embedding was performed by
infiltrating swine eyecups with 30% sucrose. Paraffin preparation of samples
was performed by dehydratation before the standard embedding procedure. For
each eye, 200–300 serial sections (14mm thick) were cut along the horizontal
meridian, and the sections were progressively distributed on glass slides so that
each slide contained 4–6 sections representative of different levels of the eye.
The sections were stained with 4¢,6¢-diamidino-2-phenylindole (Vectashield—
Vector Laboratories Inc., Peterborough, UK) or with hematoxylin and eosin
(Richard-Allen Scientific, Kalamazoo, MI, USA; Aldrich, Milan, Italy) accord-
ing to the standard protocol, and retinal histology images were obtained with
an Axioplan microscope (Carl Zeiss) with 20 magnification.
PNA, GFAP and TUNEL immunolabeling on retinal sections
Sections were rinsed in phosphate-buffered saline and incubated for 1 h in 10%
fetal bovine serum in PBT (0.1% Triton 100, 0.1% bovine serum albumin in
phosphate-buffered saline). The incubation with biotinylated peanut agglutinin
(PNA, 400mgml1 in PBT; Vector Laboratories Inc.) or with glial fibrillary
acidic protein, 1:500 in PBT (DakoCytomation, Glostrup, Denmark) was
performed overnight at 4 1C. The sections were then washed three times with
phosphate-buffered saline and incubated with Alexa Fluor 568-coupled strep-
tavidin (1:250 in PBT, Molecular Probes, Invitrogen, Carlsbad, CA, USA) for 1h
at room temperature. After a final wash, sections were mounted with 4¢,6¢-
diamidino-2-phenylindole (Vectashield), and images were obtained with a
confocal microscope Leica DMIRE2 and Leica confocal software (Leica Micro-
system, Wetzlar, Germany) with 63 magnification. Apoptotic nuclei were
detected by TdT-dUTP terminal nick-end labeling kit (TUNEL, Roche
Diagnostics, Monza, Italy) according to the manufacturer’s protocol and images
were obtained with an Axioplan microscope (Carl Zeiss) with20 magnification.
EGFP and b-Gal quantification
Collection of retinas was performed as described above (see Histological
analysis section). EGFP expression levels were measured in retinal lysates by
western blotting in 100mg of total retinal lysate. Band intensity was estimated
using the ImageJ software (NIH, version 1.41) and values (pixels inches1)
corresponding to EGFP were normalized on endogenous b-tubulin levels.
b-Gal expression levels were measured by enzyme-linked immunosorbant
assay (Roche Diagnostics) according to the manufacturer’s instructions and
normalized per microgram of retinal total lysates used. Histograms reported
the normalized EGFP values or the EGFP/b-Gal ratio.
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DNA preparation and biodistribution study
The spreading of vector DNA in tissues was determined in samples collected at
killing. Tissues (retinas, optic nerve, optic chiasm, visual thalamus, visual
cortex, muscle (tongue), lung, liver, spleen, gonads, peripheral blood mono-
nuclear cells) were collected with appropriate precautions to avoid any cross-
contamination and immediately frozen in liquid nitrogen. DNA extraction was
performed using HIRT solution, as previously reported,41 and immediately
transferred to storage in which it remained until the time of analysis. Total
copies of the AAV genome in tissue samples (vector genome copy number per
diploid genome GC (molecule per diploid genome) mdg1) were quantified by
real-time PCR using an ABI 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) and analyzed using the SDS 2.0 software
(Software Diversified Services, Spring Lake Park, MN, USA). Real-time PCR
analysis was performed on 100ng (B16 000 diploid genomes considering an
average weight for a single mdg of 6.6 pg) of HIRT-extracted genomic DNA42
using the following set of TaqMan primers/probe (PE Biosystems, Foster City,
CA, USA): forward 5¢-TCTAGTTCGCAGCCATCTGTTGT-3¢; reverse 5¢-TGG
GAGTGGCACCTTCCA-3¢; probe: 5¢-CCCCCGTGCCTTCCTTGACC-3¢, spe-
cific for the bovine growth hormone polyA. A calibration curve was prepared
using a linear AAV2-CMV-EGFP genome spanning from 5101
(B0.01:1GCmdg1) to 5107 (B3000:1GCmdg1) as template. Real-time
PCR reaction was carried out in 20ml final volume using the following
program: 1min at 94 1C, 1min at 60 1C, 1min at 72 1C for 40 cycles; the
amplification cycles were anticipated by a denaturing step (5min at 95 1C).
Identification of neutralizing antibodies against the virus capsids
The presence of NAbs against the virus capsid used in this study (AAV2/5 and
AAV2/8) was assessed on samples collected at the day of injection (preopera-
tive) and the day of killing (postoperative), as previously described.19 The
samples analyzed included the serum and the anterior chamber fluid. The NAb
titer was defined as the highest dilution that allowed EGFP to be produced to
levels corresponding to 50% of those found in control samples (in which serum
had not been added to the virus before infection).
Electroretinogram recordings
Bilateral ERG evaluations were performed using a portable ERG unit
(HMsERG model 1000, RetVet, Columbia, MO, USA), with the mini-ganzfeld
dome positioned approximately 1 cm from the right tested eye. Each ERG
session consisted of scotopic and photopic ERGs in accordance with the
International Society for Clinical Electrophysiology of Vision, recommended
by the European College of Veterinary Ophthalmology, primarily for evaluation
of rod and cone function.37 This protocol is pre-programmed on the ERG unit
and is executed automatically upon initiation of the ERG session by the
examiner. Platinum subdermal needle electrodes (model E2, Grass Instrument
Division, Astro-Med, West Warwick, RI, USA) were used for the ground
electrode, positioned on the occipital crest and for the reference electrode,
positioned 3 cm from the lateral canthus, close to the base of the right ear. An
active contact lens electrode (ERG-Jet, Universo Plastique, LKC Technologies,
Gaithersburg, MD, USA) was placed on the cornea after instillation of one drop
of 2% methylcellulose (Methocel, Ciba Vision, Munich, Germany). Rod
responses were measured in dark-adapted conditions with a light intensity of
10mcd.sm2, with 10 flashes of 2 s each and a 20ms flash lasting 180ms. The
maximal response of rods and cones was measured in dark-adapted conditions
with a light intensity of 10 cd.sm2, with four flashes of 20 s each and a 20ms
flash lasting 180ms. Cone responses were isolated in light-adapted conditions
with a background white light of 30 cd.s, a light intensity of 3 cd.sm2, with 32
flashes of 0.5 s each and a 20ms flash lasting 180ms. Cone responses using a
flicker ERG were measured in light-adapted conditions with a light intensity of
10 cd.sm2, with 128 flashes at 30Hz.
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